162706-37-8 Usage
General Description
Elinafide is a chemical compound that has been developed as a potential anti-cancer agent. It belongs to a class of drugs known as topoisomerase II inhibitors, which work by interfering with the enzyme topoisomerase II and disrupting the DNA replication process in cancer cells. This disruption ultimately leads to cell death and the inhibition of tumor growth. Elinafide has shown promising results in preclinical studies, demonstrating potent anti-cancer activity and the ability to overcome drug resistance in certain cancer cell lines. Further research and clinical trials are needed to fully evaluate the safety and effectiveness of elinafide as a potential treatment for cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 162706-37-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,2,7,0 and 6 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 162706-37:
(8*1)+(7*6)+(6*2)+(5*7)+(4*0)+(3*6)+(2*3)+(1*7)=128
128 % 10 = 8
So 162706-37-8 is a valid CAS Registry Number.
InChI:InChI=1/C31H28N4O4/c36-28-22-10-1-6-20-7-2-11-23(26(20)22)29(37)34(28)18-16-32-14-5-15-33-17-19-35-30(38)24-12-3-8-21-9-4-13-25(27(21)24)31(35)39/h1-4,6-13,32-33H,5,14-19H2
162706-37-8Relevant articles and documents
LIPOSOMAL ELINAFIDE FORMULATIONS AND USES THEREOF
-
Paragraph 0089; 0090, (2018/06/30)
The present invention provides compositions for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and elinafide, wherein less than 20% of the elinafide is released in vitro from the liposome within 40 hours. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid; and elinafide, wherein the administration of the liposomal composition has a reduced occurrence of side effects, such as for example, muscle myopathy in the patient.
